we did not perform a systematic analysis for breast and gastric cancers. All of the ten studies indicated a higher objective response for class III tubulin low/negative expression than for class III tubulin high/positive expression, and there Paclitaxel was no observed het erogeneity across the ten studies. We further investigated the heterogeneity by performing subgroup analysis. The hetero geneity was moderate at 44% in Caucasian subgroup, which might be due to difference of chemotherapy regimen. MEK Signaling Pathway Subgroup analysis based on the use of either vinorebine or paclitaxel chemotherapeutic agents was conducted to evaluate dif ferences in their performance. In eight studies patients received a paclitaxel based chemotherapy regimen, and two studies treated with vinorebine based chemotherapy regimen.
Paclitaxel based chemotherapy regimen performed a higher objective response compared with vinorebine based chemotherapy regi men. The knowledge gained ATM Signaling Pathway from this subgroup analysis implies that treatment with paclitaxel based chemotherapy regi men may be more beneficial for patient with NSCLC, compared with vinorebine based chemotherapy regimen. However, evaluation of a larger data set containing more prospective studies and a larger sample size would provide greater confidence in this apparent dif ference in efficacy between the two anti cancer agents. Publication bias is a possible limitation for this meta analysis because negative results or results opposed to mainstream theo ries are less likely to be published than papers reporting positive results.
However, we did not find that publication bias significantly influences our result of the meta analysis. In conclusion, this meta analysis provided evidence that class III tubulin low/negative expression is associated with higher response rate and has longer igf-1r survival time for the cancer patient treated with paclitaxel/vinorebine based chemotherapy. Class III tubulin could be a very useful biomarker for prognosis and sensi tivity to paclitaxel/vinorebine based chemotherapy for the patients with NSCLC. Malignant pleural mesothelioma is an increasingly common and highly aggressive cancer of the pleural mesothelium, caused by exposure to asbestos, and is considered to be highly apoptosis resistant. Currently, the licensed treatment available is a combination of antifolates with either cisplatin or carboplatin.
Vinorelbine exhibits clinical activity in both the first and the second line settings, however, to date, clinical trials have been conducted in an unselected population of patients. The BRCA1 tumour suppressor gene has been reported as a potential predictive biomarker of response to chemotherapy to antimicrotubule agents including vinorelbine, vincristine, paclitaxel, and docetaxel. canon law We have recently reported that loss of BRCA1 expression in non small cell lung cancer is sufficient to mediate sensitization to inhibition of poly ADP ribose polymerase and cisplatin. Conversely, higher levels of BRCA1 mRNA expression have been linked to better response rates and improved progression free survival, following treatment with docetaxel based first line therapy, in patients with advanced NSCLC. Accordingly, we hypothesized that BRCA1 deficiency would inhibit vinorelbine induced cell death.